Sanofi (SNY) Earnings History
Annual and quarterly earnings data from 1999 to 2025
Loading earnings history...
SNY EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SNY Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 72.3% | 13.6% | 16.7% |
| 2024 | 70.2% | 16.4% | 12.6% |
| 2023 | 69.7% | 16.7% | 13.0% |
| 2022 | 70.7% | 25.1% | 20.6% |
| 2021 | 68.7% | 20.7% | 15.9% |
Download Data
Export SNY earnings history in CSV or JSON format
Free sign-in required to download data
Sanofi (SNY) Earnings Overview
As of May 6, 2026, Sanofi (SNY) reported trailing twelve-month net income of $7.81B, reflecting -7.3% year-over-year growth. The company earned $3.20 per diluted share over the past four quarters, with a net profit margin of 16.7%.
Looking at the long-term picture, SNY's 5-year EPS compound annual growth rate (CAGR) stands at -16.2%, signaling declining earnings. The company achieved its highest annual net income of $12.29B in fiscal 2020.
Sanofi maintains industry-leading profitability with a gross margin of 72.3%, operating margin of 13.6%, and net margin of 16.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including NVO ($98.50B net income, 33.1% margin), AZN ($10.39B net income, 17.5% margin), NVS ($13.53B net income, 25.6% margin), SNY has room to improve margins relative to the peer group. Compare SNY vs NVO →
SNY Earnings vs Peers
Earnings metrics vs comparable public companies
SNY Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.81B | +40.5% | $6.34B | $2.03 | 16.7% | 13.6% |
| 2024 | $5.56B | +3.0% | $7.25B | $2.19 | 12.6% | 16.4% |
| 2023 | $5.40B | -35.5% | $6.96B | $2.15 | 13.0% | 16.7% |
| 2022 | $8.37B | +34.5% | $10.16B | $3.18 | 20.6% | 25.1% |
| 2021 | $6.22B | -49.4% | $8.13B | $2.49 | 15.9% | 20.7% |
| 2020 | $12.29B | +346.4% | $14.11B | $4.91 | 32.9% | 37.8% |
| 2019 | $2.75B | -36.0% | $3.05B | $1.14 | 7.3% | 8.1% |
| 2018 | $4.31B | -48.8% | $4.68B | $1.73 | 12.1% | 13.1% |
| 2017 | $8.42B | +78.7% | $5.80B | $3.36 | 23.2% | 16.0% |
| 2016 | $4.71B | +9.8% | $6.53B | $1.83 | 13.6% | 18.8% |
Full SNY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
Is SNY growing earnings?
SNY EPS fell to $3.20, with earnings declining -7.3%. This contrasts with the 5-year CAGR of -16.2%. TTM net income dropped to $7.8B.
What are SNY's profit margins?
Sanofi net margin is +16.7%, with operating margin at +13.6%. Above-average margins indicate pricing power.
How consistent are SNY's earnings?
SNY earnings data spans 1999-2025. The declining earnings trend is -7.3% YoY. Historical data enables comparison across business cycles.